-
Mashup Score: 2FDA Approves Obecabtagene Autoleucel in B-Cell ALL - 2 month(s) ago
Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 12
In patients with positive-minimal residual disease at transplantation, de novo chronic myeloid leukemia in blastic phase was significantly associated with superior disease-free survival compared with…
Categories: General Medicine News, Oncologists1Tweet-
New | Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation https://t.co/VQ1tsrWU08 @OncoAlert #leusm https://t.co/3tIqnsdTE4
-
-
Mashup Score: 2FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia - 2 month(s) ago
The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
🚨 BREAKING 🚨: @US_FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia #leusm https://t.co/EeHLopKw8A https://t.co/JhvkSAjdIh
-
-
Mashup Score: 3Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML - 2 month(s) ago
Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML @GCC_Cortes @GACancerCenter #leusm https://t.co/nkGKHVOSZN
-
-
Mashup Score: 0
Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Combining uproleselan with 7+3 chemotherapy did not significantly improve EFS vs chemotherapy alone among patients 60 years and older who have newly diagnosed AML and eligibility to undergo intensive chemotherapy. #leusm https://t.co/iKbUAdiFDs
-
-
Mashup Score: 3FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia - 2 month(s) ago
The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
🚨 BREAKING 🚨: @US_FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia #leusm https://t.co/EeHLopKw8A https://t.co/JhvkSAjdIh
-
-
Mashup Score: 5Asciminib Yields Promising Efficacy vs SOC Agents in CML - 2 month(s) ago
Jorge Cortes, MD, details how asciminib could affect care for patients with CML, diving into key takeaways from the ASC4FIRST trial.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The efficacy and tolerable safety profile of asciminib make it a promising potential agent that could be used in the frontline setting if approved for patients with chronic myeloid leukemia. @GCC_Cortes @GACancerCenter #leusm https://t.co/e9zzpCoaVR https://t.co/z4aX5nnje2
-
-
Mashup Score: 1
Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
.@US_FDA approves asciminib for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. #leusm | @FDAOncology https://t.co/xWkXnM1chn https://t.co/UfJjb6iHIb
-
-
Mashup Score: 3FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia - 2 month(s) ago
The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
🚨 BREAKING 🚨: @US_FDA Expands Approval of Methotrexate to Include Pediatric Acute Lymphoblastic Leukemia #leusm https://t.co/EeHLopKw8A https://t.co/JhvkSAjdIh
-
-
Mashup Score: 3Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML - 2 month(s) ago
Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML @GCC_Cortes @GACancerCenter #leusm https://t.co/nkGKHVOSZN
-
.@US_FDA approves obecabtagene autoleucel for patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. #leusm | @FDAOncology https://t.co/LNFygPQMOR https://t.co/5rZP6LI2j1